Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
37.78
+0.01 (0.03%)
Nov 13, 2024, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Revenue
Ionis Pharmaceuticals had revenue of $133.81M in the quarter ending September 30, 2024, a decrease of -7.21%. This brings the company's revenue in the last twelve months to $803.07M, up 30.57% year-over-year. In the year 2023, Ionis Pharmaceuticals had annual revenue of $787.65M with 34.10% growth.
Revenue (ttm)
$803.07M
Revenue Growth
+30.57%
P/S Ratio
6.87
Revenue / Employee
$866,307
Employees
927
Market Cap
5.97B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
R1 RCM | 2.46B |
RadNet | 1.77B |
Lantheus Holdings | 1.50B |
Merit Medical Systems | 1.33B |
Stevanato Group | 1.22B |
Inspire Medical Systems | 755.59M |
Corcept Therapeutics | 628.56M |
Blueprint Medicines | 434.42M |
IONS News
- 6 days ago - Ionis to present at upcoming investor conferences - PRNewsWire
- 7 days ago - Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - PRNewsWire
- 7 days ago - Ionis reports third quarter 2024 financial results - PRNewsWire
- 9 days ago - Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - PRNewsWire
- 21 days ago - Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling - Seeking Alpha
- 21 days ago - Ionis to hold third quarter 2024 financial results webcast - PRNewsWire
- 23 days ago - WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - PRNewsWire